AERS Overhaul Will Be Overseen By FDA’s New Bioinformatics Board

FDA's initiative to develop an advanced Adverse Event Reporting System that has the ability to analyze data and assist medical reviewers in their efforts to spot safety signals will be overseen by a new Bioinformatics Board